Stay updated on Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.

Latest updates to the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedLocations sections were consolidated under a single 'Locations' header and now list California, District of Columbia, Illinois, Missouri, New York, and Texas; the HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.SummaryDifference0.8%

- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedThe page shows a minor revision update: Revision: v3.3.2 was added and Revision: v3.3.1 was removed; core study details, eligibility criteria, endpoints, and results remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now displays a new revision note: Revision: v3.3.1, replacing the previous v3.2.0, while the core study details and eligibility information appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedRemoved a generic notice about funding-related outages and the NIH Clinical Center's operating status from the page. The study content and eligibility details remain unchanged.SummaryDifference0.4%

- Check70 days agoChange DetectedNo additions or deletions were detected; the page content remains unchanged.SummaryDifference0.4%

- Check99 days agoChange DetectedMajor change: version bump to v3.2.0 and an important operating-status notice about government funding and NIH Clinical Center, directing users to official sources.SummaryDifference3%

Stay in the know with updates to Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.